Research programme: malononitrilamide compounds - Sanofi-Aventis/Astellas Pharma

Drug Profile

Research programme: malononitrilamide compounds - Sanofi-Aventis/Astellas Pharma

Alternative Names: Malononitrilamide compounds research programme - Sanofi-Aventis/Fujisawa

Latest Information Update: 18 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Nitriles
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in Europe (unspecified route)
  • 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top